Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

General Updates | Identifying novel antigens for TCR T-cell therapy

David Apelian • 29 Apr 2022
General Updates
General Leukemia

David Apelian, MD, PhD, BlueSphere Bio, Pittsburgh, PA, discusses work he is involved with on the first minor histocompatibility antigen (miHA) platform to treat patients with high-risk leukemia undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). In addition, work is being done to identify novel shared antigens that can be targeted by T-cell receptor (TCR) T-cells before achieving a fully personalized treatment platform to treat patients. This interview was recorded virtually.

More from David Apelian

3:17
TCXpress™ vs CAR-T therapy & targeting leukemia with TCR T-cells
David Apelian • 29 Apr 2022
2:16
TCXpress™, a novel promising TCR platform
David Apelian • 29 Apr 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals